FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

HHS Inspector General Probe on Alexion Practices

The HHS Office of Inspector General discloses it has opened an investigation into Alexion Pharmaceuticals business practices.

Federal Register

Joint Panel to Review NDA for Pain Drug

Federal Register notice: FDA announces a 7/26 joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and R...

Human Drugs

Consent Decree Ordered Against Medistat RX

FDA agrees to a consent decree of permanent injunction against Medistat RX LLC (Foley, AL) and certain company officials due to making non-sterile dru...

FDA General

House Hearing to Review FDA Off-label Enforcement

The House Energy and Commerce Subcommittee on Health announces a 7/12 hearing on Examining Medical Product Manufacturer Communications, including FDA ...

Medical Devices

No New Bleeding Reports With Baxter Vascular Patch: FDA

FDA says that it has not received any additional adverse events associated with severe bleeding and hematomas with Baxter Internationals Vascu-Guard p...

Human Drugs

FDA Approves New Sickle Cell Therapy

FDA approves an Emmaus Medical NDA for Endari (L-glutamine oral powder) for patients five years and older with sickle cell disease to reduce severe c...

Federal Register

Panel to Review Expanded Use for Pfizers Xeljanz

Federal Register notice: FDA announces an 8/3 Arthritis Advisory Committee meeting that will review a Pfizer supplemental NDA for Xeljanz (tofacitinib...

Human Drugs

Sen. Hatch Bill Would Increase Orphan Drug Incentives

Senator Orrin Hatch (R-UT) introduces the Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2017.

FDA General

Latest FDA Warning Letters

FDA releases its latest batch of Warning Letters that includes one medical product company Shandong Analysis and Test Center.

FDA General

FDA Posts Work Plan on Implementing Cures Act

FDA releases a draft work plan outlining how it will allocate $500 million over the next nine years to implement the 21st Century Cures Act.